UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of ~~Earliest~~earliest ~~Event~~event ~~Reported~~reported): ~~May~~June 3015, 2018

ANTHERA PHARMACEUTICALS, INC.

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware	001-34637	~~20-1852016~~	20-1852016
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)		(I.R.S. Employer Identification No.)
25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of Principal Executive Offices)		(Zip Code)

25801 Industrial Boulevard, Suite B, Hayward, California		94545
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8 5.~~01.~~02 Departure ~~Other~~of ~~Events~~Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On ~~May~~June 3015, 2018, Anthera Pharmaceuticals, Inc., (the “Company”) and Craig Thompson entered into a ~~Delaware~~letter ~~corporation~~agreement (the “~~Company~~Letter Agreement”), ~~announced~~amending ~~that~~Mr. itThompson’s ~~will~~Amended ~~hold~~and Restated Employment Agreement with the Company’s dated January 5, 2018 ~~annual~~(the ~~meeting~~“Employment onAgreement”). ~~December~~Pursuant 3to the terms of the Letter Agreement, Mr. Thompson acknowledged and agreed that, among other things, (i) from June 15, 2018 through June 30, 2018 (the “~~2018~~Transition ~~Annual~~Period”), ~~Meeting~~he shall only be required to devote 20% of his working time and efforts to the business and affairs of the Company, (ii) during the Transition Period he shall receive an annualized base salary in the amount of $92,000, provided that for purposes of his severance eligibility as set forth in Section 5(b) of the Employment Agreement, his “Base Salary” shall be based on his full salary of $460,000, and (iii)~~. Further~~ ~~information~~his ~~regarding~~employment with the Company shall end effective as of June 30, 2018. ~~Annual~~The ~~Meeting~~parties ~~will~~agreed that such separation of employment shall be ~~made~~deemed ~~available~~a “Termination without Cause,” and, subject to ~~stockholders~~the interms aof ~~definitive~~his ~~proxy~~Employment ~~statement~~Agreement, ~~which~~Mr. ~~will~~Thompson shall be ~~filed~~entitled to receive severance benefits set forth in Section 5(b) of the Employment Agreement subject to his execution and non-revocation of a separation and release agreement and continued compliance with his contractual obligations to the ~~Securities~~Company. Mr. Thompson will continue to serve as President, Chief Executive Officer, as a director on the Company’s Board of Directors, and ~~Exchange~~provide ~~Commission~~consulting (services to the ~~“SEC”)~~Company after the termination of his Employment Agreement.

~~Stockholders~~The ~~who~~foregoing ~~meet~~summary ~~the requirements~~ of the ~~proxy~~Letter ~~rules~~Agreement ~~under~~does ~~the~~not ~~Securities~~purport ~~Exchange Act of 1934, as amended (the “Exchange Act”), may submit proposals~~ to ~~the~~be ~~Company’s~~complete ~~Board~~and ofis ~~Directors~~subject ~~(the “Board”)~~ to, ~~be presented at the 2018 Annual Meeting. Such proposals must comply with the requirements of Rule 14a-8 under the Exchange Act~~ and bequalified ~~submitted~~ in ~~writing~~its byentirety ~~notice delivered or mailed~~ by ~~first-class United States mail~~, ~~postage~~the ~~prepaid,~~full totext ~~our~~of ~~Secretary at our principal executive offices at~~ the ~~address~~Letter ~~set~~Agreement, ~~forth~~a ~~above~~copy noof ~~later~~which ~~than~~is ~~October~~filed 4,as ~~2018~~Exhibit in10.1 ~~order~~ to bethis ~~considered~~Current ~~for~~Report ~~inclusion~~and inis ~~the~~incorporated ~~proxy~~herein ~~materials to be disseminated~~ by ~~the Board for the 2018 Annual Meeting~~reference.

~~Stockholders~~Item who desire to bring business before the 2018 Annual Meeting, other than through a shareholder proposal pursuant to the SEC’s rules, must notify the Company’s Secretary in writing and provide the information required by the provision of the Company’s Amended and Restated Bylaws dealing with shareholder proposals9.01 ~~Notice~~Financial ~~must~~Statements ~~be received at the Company’s principal executive offices no later than October 4, 2018. The requirements for such notice are set forth in the Company’s Amended~~ and Restated Bylaws. The Company reserves the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements.Exhibits

Exhibit 10.1

Letter Agreement between Anthera Pharmaceuticals, Inc. and Craig Thompson, dated June 15, 2018.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 30, 2018	Anthera Pharmaceuticals, Inc.
Date: June 18, 2018	Anthera Pharmaceuticals, Inc.
	By:	/s/ J. Craig Thompson
		J. Craig Thompson
		President and CEO
		President and Chief Executive Officer
		(Principal Executive Officer)

EXHIBIT INDEX



Exhibit No.	Description

10.1	Letter Agreement between Anthera Pharmaceuticals, Inc. and Craig Thompson, dated June 15, 2018.

Filing Compare · Anthera Pharmaceuticals Inc